NASDAQ: EGRX - Eagle Pharmaceuticals, Inc.

Rentabilidade por seis meses: -90.44%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Eagle Pharmaceuticals, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

mais detalhes
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2014-02-12
ISIN US2697961082
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.eagleus.com
Цена ао 5.04
Alteração de preço por dia: -2% (0.5102)
Alteração de preço por semana: -9.09% (0.55)
Alteração de preço por mês: -29.58% (0.71)
Alteração de preço em 3 meses: -87.34% (3.95)
Mudança de preço em seis meses: -90.44% (5.23)
Mudança de preço por ano: -90.44% (5.23)
Mudança de preço em 3 anos: -99.1% (55.42)
Mudança de preço em 5 anos: -99.11% (56.22)
Mudança de preço em 10 anos: 0% (0.5)
Mudança de preço desde o início do ano: -47.37% (0.95)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 1.2 9
P/BV 1.63 8
P/E 10.67 9
EV/EBITDA 5.92 9
Total: 9

Eficiência

Nome Significado Nota
ROA, % 10.8 4
ROE, % 17.39 5
Total: 4.33

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0.2257

Obrigação

Nome Significado Nota
Debt/EBITDA 0.9542 9
Total: 7.2

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 48.43 6
Rentabilidade Ebitda, % 91.84 9
Rentabilidade EPS, % 30.52 5
Total: 4.4
Mais detalhes

Instituições Volume Compartilhar, %
Blackrock Inc. 984908 7.58
Janus Henderson Group PLC 775525 5.97
Brandes Investment Partners L.P. 745080 5.74
Vanguard Group Inc 638124 4.91
Millennium Management LLC 522402 4.02
AQR Capital Management, LLC 493665 3.8
LSV Asset Management 391758 3.02
Morgan Stanley 296864 2.29
Renaissance Technologies, LLC 294450 2.27
Acadian Asset Management. LLC 287555 2.21

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Royce Quant Small‑Cap Quality Value ETF 0.19827 21.83 1.62596
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01366 17.58 1.75869
iShares Micro-Cap ETF 0.01037 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.00121 17.47 1.51433



Supervisor Cargo Pagamento Ano de nascimento
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 160k 1963 (62 ano)
Dr. Valentin R. Curt M.D. Senior Vice President of Clinical Drug Development N/A
Dr. Gaozhong Zhu Ph.D. Senior Vice President of Pharmaceutical Development N/A
Mr. Reed McClung Executive Vice President of Oncology Business Development N/A
Mr. Steven B. Ratoff Interim CFO, Principal Accounting Officer & Director 100k 1943 (82 ano)
Mr. Daniel O'Connor Executive VP, Chief Strategy Officer & Head of Corporate Development 1980 (45 anos)
Ms. Debra Marie Hussain Senior VP & Head of Commercial 1968 (57 anos)

Endereço: United States, Woodcliff Lake. NJ, 50 Tice Boulevard - abrir no Google Maps, abrir mapas Yandex
Site: https://www.eagleus.com